Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I non-viral EPHB4-targeted CAR-T cell therapy study in Ewing sarcoma or EPHB4-positive solid tumors
jRCT2033230299Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACS2015 in Ewing sarcoma and Nonhematologic neoplasms, sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Dose-limiting toxicities. Started Oct 2023; status: recruiting.
02
Drugs
ACS2015
03
Conditions
Ewing sarcomaNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2033230299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033230299.